Despite differences in methodology to quantify irisin concentrations, systemic irisin levels are increased in obesity which may reduce the potential of using irisin as a therapeutic agent, although levels are likely decreased in T2DM (144). The gene discussed is FNDC5; the disease is type 2 diabetes mellitus.